

Electronic Acknowledgement Receipt

EFS ID:	4193960
Application Number:	10551985
International Application Number:	
Confirmation Number:	3306
Title of Invention:	4-(4-(Heterocyclakoxy) phenyl-1-(heterocyclyl-carbonyl) piperidine derivavites and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's
First Named Inventor/Applicant Name:	Mark James Bamford
Customer Number:	23347
Filer:	James P. Riek/Rebecca Kerney
Filer Authorized By:	James P. Riek
Attorney Docket Number:	B60199USw
Receipt Date:	29-OCT-2008
Filing Date:	04-OCT-2005
Time Stamp:	09:36:05
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 1250
RAM confirmation Number	5510
Deposit Account	071392
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		PB60199USw_Amendment.pdf	110711 84f2286880ca23b5e538aaa9dd99e268af358ac6	yes	12
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment/Req. Reconsideration-After Non-Final Reject		1	1	
	Claims		2	8	
	Applicant Arguments/Remarks Made in an Amendment		9	12	
Warnings:					
Information:					
2	Terminal Disclaimer Filed	PB60199USw_Terminal_Disclaimer_over_USSN11246480.pdf	263228 7efd3f7a2631a22fd2e81308b125e0b0fb2b87da	no	2
Warnings:					
Information:					
3	Fee Worksheet (PTO-06)	fee-info.pdf	32400 c0c1ed0b1f8b4989bb19751a513a5d5123400e67	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			406339		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.